Waltermire Robert E. 4

Accession 0001628280-25-011405

CIK 0001157601other

View on SEC.gov Company Profile

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 5:40 PM ET

Size

29.9 KB

Accession

0001628280-25-011405

Insider Transaction Report

Form 4

Period: 2025-03-05

MADRIGAL PHARMACEUTICALS, INC.MDGL

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Transactions

Sale
Common Stock
2025-03-05$343.85/sh−4,701$1,616,429→ 5,140 total
Award
Common Stock
2025-03-05+2,061→ 5,789 total
Exercise/Conversion
Common Stock
2025-03-05$87.92/sh+6,825$600,054→ 10,553 total
Sale
Common Stock
2025-03-05$336.78/sh−1,777$598,457→ 15,164 total
Sale
Common Stock
2025-03-05$342.90/sh−1,077$369,300→ 9,841 total
Award
Stock Option (Right to Buy)
2025-03-05+1,157→ 1,157 total
Exercise: $347.28Exp: 2035-03-05→ Common Stock (1,157 underlying)
Sale
Common Stock
2025-03-05$338.09/sh−1,146$387,452→ 14,018 total
Sale
Common Stock
2025-03-05$340.75/sh−1,657$564,627→ 11,961 total
Sale
Common Stock
2025-03-05$341.84/sh−1,043$356,537→ 10,918 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-03-05−6,825→ 4,375 total
Exercise: $87.92Exp: 2031-08-02→ Common Stock (6,825 underlying)
Exercise/Conversion
Common Stock
2025-03-05$87.09/sh+7,288$634,712→ 17,841 total
Sale
Common Stock
2025-03-05$335.15/sh−900$301,631→ 16,941 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-03-05−7,288→ 3,062 total
Exercise: $87.09Exp: 2032-02-22→ Common Stock (7,288 underlying)
Sale
Common Stock
2025-03-05$339.68/sh−400$135,874→ 13,618 total
Sale
Common Stock
2025-03-05$344.76/sh−1,412$486,797→ 3,728 total

Footnotes (13)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.005 to $335.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
[F10]Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.
[F11]All shares issued pursuant to the exercise of the options reported herein represent 6,825 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
[F12]All shares issued pursuant to the exercise of the options reported herein represent 7,288 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
[F13]The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.445 to $337.44, inclusive.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.47 to $338.44, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.21 to $340.14, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.24 to $341.18, inclusive.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.24 to $342.05, inclusive.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.30 to $343.29, inclusive.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $343.31 to $344.30, inclusive.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.31 to $345.07, inclusive.

Documents

1 file

4
wk-form4_1741387197.xmlPrimary
FORM 4

Issuer

MADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

→

Entity typeother

Related Parties

filerCIK 0001876996

Filing Metadata

Form type: 4
Filed: Mar 6, 7:00 PM ET
Accepted: Mar 7, 5:40 PM ET
Size: 29.9 KB

View on SEC.gov